| Defective glycosylation leads to defective gp130-dependent STAT3 signaling in PGM3-deficient patients M Ben-Ali, L Ben-Khemis, N Mekki, R Yaakoubi, R Ouni, ... Journal of Allergy and Clinical Immunology 143 (4), 1638-1640. e2, 2019 | 19 | 2019 |
| Granzyme B induced by Rv0140 antigen discriminates latently infected from active tuberculosis individuals R Ouni, H Gharsalli, V Dirix, A Braiek, N Sendi, A Jarraya, ... Journal of leukocyte biology 105 (2), 297-306, 2019 | 7 | 2019 |
| Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings C Benabdessalem, WB Hamouda, S Marzouki, R Faye, AA Mbow, B Diouf, ... Diagnostic Microbiology and Infectious Disease 105 (4), 115903, 2023 | 5 | 2023 |
| Culture filtrate protein 32 as a potential target to attenuate the heterogeneous antibody response against Mycobacterium tuberculosis Antigens in different endemic settings C Benabdessalem, R Ouni, WB Hamouda, J Bettaieb, DM Fathallah, ... The International Journal of Mycobacteriology 11 (4), 378-383, 2022 | 2 | 2022 |
| N-glycosylation and homodimeric folding significantly enhance the immunoreactivity of Mycobacterium tuberculosis virulence factor CFP32 when produced in the yeast Pichia pastoris C Benabdessalem, H Othman, R Ouni, N Ghouibi, A Dahman, R Riahi, ... Biochemical and biophysical research communications 516 (3), 845-850, 2019 | 2 | 2019 |
| COVID-19 in Tunisia (North Africa): IgG and IgG subclass antibody responses to SARS-CoV-2 according to disease severity (preprint) C Benabdessalem, S Marzouki, WB Hamouda, K Trabelsi, M Boumaiza, ... | 1 | 2022 |
| HBHA-IGRA and cytotoxic mediators release assays for the diagnosis of cervical tuberculous lymphadenitis S Bchiri, A Bouzekri, R Ouni, R Lahiani, E Romdhane, N Dekhil, ... Microbiology Spectrum 11 (6), e01638-23, 2023 | | 2023 |
| COVID-19 in Tunisia (North Africa): IgG and IgG subclass antibody responses to SARS-CoV-2 according to disease severity C Benabdessalem, S Marzouki, WB Hamouda, K Trabelsi, M Boumaiza, ... medRxiv, 2022.03. 01.22271696, 2022 | | 2022 |
| CFP32 as a target to attenuate the heterogeneous antibody response against Mycobacterium tuberculosis antigens in different endemic settings C Benabdessalem, R Ouni, W Ben Hamouda, J Bettaieb, DM Fathallah, ... Available at SSRN 4100350, 0 | | |
